tradingkey.logo
tradingkey.logo
Search

BridgeBio Pharma Says Acoramidis Reduces CVM Or CVH Risk By 49% Through Month 30

ReutersSep 28, 2025 3:18 PM
facebooktwitterlinkedin
View all comments0

- BridgeBio Pharma Inc BBIO.O:

  • ACORAMIDIS BEGINS TO REDUCE CUMULATIVE CARDIOVASCULAR OUTCOMES WITHIN THE FIRST MONTH OF TREATMENT IN PATIENTS WITH ATTR-CM

  • BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES CVM OR CVH RISK BY 49% THROUGH MONTH 30

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI